Most analysts calling for much more. Ave estimate is $15.79 for ACRX and high of $20 (this is not that far-fetched with the way this is being moved forward by awesome management team). About 4 months to PDUFA, don't forget to get in this rocket ship ASAP (the doors will be locked shut soon), chasing will result in getting scorched by booster packs.
FOLKS, there are like 3 seats left and the doors are shutting, everyone willing to pay up for a seat, do not to miss out on this PDUFA run. Big pharma has to be looking under the hood of ACRX. If Impax is wanting DRRX pain patch and ENDO bought PATH out for pain patch, you can see something in that. ACRX is going way higher.
Another example: PCRX - 2.7 Billion market cap from a convenient bupivacaine. ACRX just at $550M, not only is it convenient, but its much more safe than the standard of treatment right now. Has the chance to replace THE ENTIRE standard of care when it comes to PCA. Every hospital will want this.